Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

4D Molecular Therapeutics (FDMT) Equity Average (2020 - 2025)

4D Molecular Therapeutics (FDMT) has disclosed Equity Average for 6 consecutive years, with $437.3 million as the latest value for Q4 2025.

  • Quarterly Equity Average fell 17.76% to $437.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $437.3 million through Dec 2025, down 17.76% year-over-year, with the annual reading at $508.1 million for FY2025, 24.17% up from the prior year.
  • Equity Average for Q4 2025 was $437.3 million at 4D Molecular Therapeutics, up from $394.9 million in the prior quarter.
  • The five-year high for Equity Average was $594.5 million in Q2 2024, with the low at $225.0 million in Q1 2023.
  • Average Equity Average over 5 years is $357.6 million, with a median of $313.2 million recorded in 2022.
  • The sharpest move saw Equity Average surged 415.68% in 2021, then crashed 30.79% in 2025.
  • Over 5 years, Equity Average stood at $271.6 million in 2021, then fell by 11.13% to $241.4 million in 2022, then soared by 32.1% to $318.9 million in 2023, then surged by 66.76% to $531.8 million in 2024, then decreased by 17.76% to $437.3 million in 2025.
  • According to Business Quant data, Equity Average over the past three periods came in at $437.3 million, $394.9 million, and $445.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.